{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-037183","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.995274+00:00","generated_at":"2026-06-08T15:54:07.981348+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bioventus reports Q3 net sales $120.8M (-6.1% YoY), raises 2023 adjusted EBITDA guidance","bullets":["Net loss from continuing ops improved to $8.8M from $101.0M in Q3 2022; loss per share $0.12 vs $1.18.","Adjusted EBITDA from continuing ops $21.7M, down 0.9% YoY; non-GAAP EPS $0.05 vs $0.18.","Pain Treatments revenue grew 3.1% YoY to $53.7M; Surgical Solutions up 5.7% in U.S.","Raised full-year 2023 guidance: net sales $498-505M, adjusted EBITDA $84-87M.","Restorative Therapies fell 34.8% due to Wound Business divestiture; underlying organic sales down 0.5%."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-037183","json":"https://secwatch.observer/filing/0001628280-23-037183.json","markdown":"https://secwatch.observer/filing/0001628280-23-037183.md","text":"https://secwatch.observer/filing/0001628280-23-037183.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000162828023037183/0001628280-23-037183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000162828023037183/bvs-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T15:54:07.981348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18a2cb2ead6cb0f9f4879755ee5e4969d66a6c0e","claim":"Bioventus Inc. reported the three and nine months ended September 30, 2023 results: revenue $120.8 million, net income Net Loss from continuing operations of $8.8 million, EPS Loss per share of Class A common stock from continuing operations of $0.12. Guidance raised.","evidence_excerpt":"a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 30, 2023. Q3 Financial Summary: • Net Sales of $120.8 million, down $7.9 million, or 6.1%, year-over-year as reported (6.3% constant currency*). Excluding revenues from divested wound assets, underlying organic sales decreased $0.6 million,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828023037183/0001628280-23-037183-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2023"},{"label":"Revenue","value":"$120.8 million"},{"label":"Net income","value":"Net Loss from continuing operations of $8.8 million"},{"label":"EPS","value":"Loss per share of Class A common stock from continuing operations of $0.12"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}